Mineralys 治療公司
US ˙ NasdaqGS ˙ US6031701013

SecurityMLYS / Mineralys Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership67,795 shares
Latest Disclosed Value $ 917,266
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 38.77% increase in ownership of MLYS / Mineralys Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 67,795 shares of Mineralys Therapeutics, Inc. (US:MLYS) valued at $917,266 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 48,855 shares of Mineralys Therapeutics, Inc.. This represents a change in shares of 38.77% during the quarter. The current value of the position is $1,606,064 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Mineralys Therapeutics EC US6031701013 67,795 18,940 38.77 917 18.32 0.0206
2025-05-28 2025-03-31 NP Mineralys Therapeutics EC US6031701013 48,855 0 0.00 776 28.95 0.0186
2025-02-25 2024-12-31 NP Mineralys Therapeutics EC US6031701013 48,855 -8,080 -14.19 601 -12.77 0.0131
2024-11-26 2024-09-30 NP Mineralys Therapeutics EC US6031701013 56,935 20,727 57.24 689 62.88 0.0130
2024-08-26 2024-06-30 NP Mineralys Therapeutics EC US6031701013 36,208 12,135 50.41 424 36.45 0.0086
2024-05-28 2024-03-31 NP Mineralys Therapeutics EC US6031701013 24,073 0 0.00 311 49.76 0.0065
2024-02-26 2023-12-31 NP Mineralys Therapeutics EC US6031701013 24,073 0 0.00 207 -9.21 0.0044
2023-11-28 2023-09-30 NP Mineralys Therapeutics EC US6031701013 24,073 0 0.00 229 -44.39 0.0060
2023-08-25 2023-06-30 NP Mineralys Therapeutics EC US6031701013 24,073 6,066 33.69 410 45.91 0.0097
2023-05-26 2023-03-31 NP Mineralys Therapeutics EC US6031701013 18,007 18,007 282 0.0075
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.